

Bladder Cancer Index (BCI)

TECHNOLOGY NUMBER: 2020-074



OVERVIEW

Health related quality of life measure for patients diagnosed with bladder cancer with emphasis on treatment related patient reported outcomes in the urinary, bowel and sexual domains.

- Quality of life Measure
- Open Access Creative Commons Attribution-NonCommercial-No Derivatives 4.0
 International (CC BY-NC-ND 4.0)

BACKGROUND

The Bladder Cancer Index (BCI) was developed by researchers at the University of Michigan to measure health related quality of life among men with bladder cancer. It represents an adaptation of the UCLA Prostate Cancer Index, modified to enhance sensitivity to therapy effects by increasing the number of prostate-targeted items to 50 (compared to 20 in the original UCLA-PCI).

ADDITIONAL DETAILS

REFERENCES:

Gilbert, S. M., Dunn, R. L., Hollenbeck, B. K., Montie, J. E., Lee, C. T., Wood, D. P., & Wei, J. T. (2010). Development and Validation of the Bladder Cancer Index: A comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. The

Technology ID

2020-074

Category

Content Life Sciences

Inventor

Scott Gilbert John Wei Rod Dunn David Wood Cheryl Lee James Montie Brent Hollenbeck

Further information

Drew Bennett andbenne@umich.edu

Learn more



Journal of Urology, 183(5), 1764–1770. https://doi.org/10.1016/j.juro.2010.01.013

INTELLECTUAL PROPERTY:

(c) 2010 The Regents of the University of Michigan The Bladder Cancer Index (BC) is licensed under the Creative Commons Attribution-No Derivatives 4.0 International (CC BY-ND 4.0) License.